The altered expression of both p53 and erbB2 is strongly related to the disease status and the outcome of bladder cancers. We examined the antitumor efficacy by the modulation of these genetic alterations with a newly designed dual-gene-expressing adenovirus (Ad-p53/erbB2Rz), which expresses p53 and anti-erbB2 ribozyme simultaneously in human bladder cancer cells. Cell growth inhibition efficacy along with biological responses of this virus was compared with other viral vectors (Ad-p53, which expresses wild-type p53 cDNA, and Ad-erbB2Rz, which expresses anti-erbB2 ribozyme, solely or in combination). Sufficient transgene expression in targeted cells and the altered expression of the targeted genes and their encoded proteins were obtained by each therapeutic vector. Each of the three therapeutic viral vectors inhibited bladder cancer cell growth, and the putative additive antitumor effect was shown by the combination of two of the therapeutic vectors. Furthermore, Ad-p53/erbB2Rz had superior therapeutic efficacy when the same titers of viruses were infected. Nonspecific vector-related toxicity was minimized by reducing the total amount of viral titers by using the dual-gene-expressing adenovirus. Modulation of multiple genetic abnormalities might enhance the therapeutic efficacy, and vector-related toxicity could be minimized when the total amount of viral titers are reduced.
Introduction
Cancer treatment by modulation of genetic alteration has been widely examined and adopted in clinical trials. Since the development and progression of cancer is generally caused by multiple genetic alterations, the therapeutic efficacy of the correction of a single genetic alteration might not be sufficient even if it inhibits cancer growth to various degrees. Some strategies, therefore, adopted a combination of chemotherapeutic agents or irradiation along with gene therapy, resulting in improved therapeutic efficacy. The transduction of multiple therapeutic genes, targeted to the genetic abnormalities related to cancer development and growth, might have potential for enhancing the therapeutic efficacy. The strategies of genetic modulation by a combination of transduction of suppressor gene and inhibition of oncogene have not been reported to date. In the present study, we developed a novel technology for simultaneous expression of two therapeutic genes (i.e., tumor-suppressor gene and antioncogene molecule) from a single adenoviral vector using the appropriate promoter and examined the antitumor efficacy of this system.
As of today, treatment results of bladder cancer are not satisfying, especially for muscle invasive and metastatic disease, and innovative therapeutic strategies are desired. Gene-based therapy of bladder cancer has been widely examined, and encouraging results have been observed preclinically. 1 Bladder cancer might be one of the appropriate targets for gene therapy because of its wellelucidated molecular pathway. Genetic abnormalities associated with carcinogenesis and progression of bladder cancer have been clarified at least partially, and involve two major pathways. One causes superficial cancer, and the other causes invasive cancer and high-grade carcinoma in situ.
2 p53 is a well-known tumor-suppressor gene; the altered expression of p53 has been described in nearly half of bladder cancers.
3 p53 is thought to play an important role especially in the progression of invasive bladder cancer. Inactivation of p53 can occur by point mutations, accompanied by the loss of the wild-type p53 allele. The incidence of p53 alteration increases in a grade-and stage-dependent manner, and nuclear mutant p53 is associated with a higher risk of recurrence after radical cystectomy and lower overall survival. 4, 5 The proto-oncogene erbB2 (also called HER2/neu) is also thought to be closely associated with the invasive phenotype of bladder cancer. erbB2 is a part of the epidermal growth factor receptor family and possesses tyrosine kinase activity. Overexpression of erbB2 is seen in 20-40% of bladder cancers and accelerates cell proliferation. 6 Expression of the erbB2 gene product is reported to be a significant prognostic factor independent of grade and stage of the tumor. 7 The relationship of p53 mutation and erbB2 overexpression has been reported for superficial bladder cancer, and clinical outcome of the cases with both alterations was poor. 8, 9 A poor clinical prognosis for patients with invasive bladder cancer coexpressing p53 and erbB2 also has been demonstrated. 10 It is hypothesized that correction of these alterations by wildtype p53 restoration and erbB2 inhibition may have a favorable therapeutic effect against bladder cancers, especially those with invasive and metastatic status.
Adenoviruses are one of the most extensively investigated delivery systems in gene therapy for cancer, and their usefulness has been widely demonstrated. However, nonspecific vector-related cytotoxicity of adenoviruses has been reported and is one of the major obstacles to development of ideal vector system. 11 These vectorrelated adverse events could be minimized by reducing the total amount of viral particles and by improving the transduction efficacy of therapeutic genes. To reduce the amount of viral vector, we constructed a replicationdeficient dual-gene-expressing adenovirus. To improve the gene transduction efficiency, we applied a polymerase III (pol III) promoter in driving ribozymes because pol III promoters are more efficient for expressing small molecules such as antisense oligonucleotides and ribozymes. 12 In the present study, an adenovirus that simultaneously expresses cytomegalovirus (CMV) promoter-driven wildtype p53 and pol III-driven anti-erbB2 ribozyme was designed, and its antitumor efficacy was elucidated against human bladder cancer cells.
Materials and methods

Construction of the adenoviral vectors
Three different replication-deficient adenoviral vectors were constructed: an adenovirus expressing wild-type p53 (Ad-p53), an adenovirus-expressing anti-erbB2 ribozyme (Ad-erbB2Rz), and a third adenoviral vector expressing both wild-type p53 and anti-erbB2 ribozyme simultaneously (Ad-p53/erbB2Rz) ( Figure 1 ). In two adenoviruses, Ad-p53 and Ad-erbB2Rz, therapeutic genes were constructed to be driven by human CMV promoter/ enhancer. In Ad-p53/erbB2Rz, p53 was recombined to be expressed by human CMV promoter/enhancer, and antierbB2 ribozyme was constructed to be driven by a pol III promoter.
The inserted cDNA of wild-type human p53 was obtained from the American Type Culture Collection (ATCC 57254; Rockville, MD). The hammerhead ribozyme against erbB2 RNA was designed to hybridize to the codon 70-74 of the erbB2 proto-oncogene and to cleave the GUC sequence at codon 71-72 ( Figure 2 ). The oligonucleotide fragment of anti-erbB2 ribozyme for Ad-erbB2Rz was constructed from two synthesized oligonucleotides; 5 0 -TCGACAGGAAGCTGATGAGTC CGTGAGGACGAAACAGGCTA-3 0 and 5 0 -AGCTTA GCCTGTTTCGTCCTCACGGACTCATCAGCTTCC TG-3 0 . These oligonucleotide sequences, which include SalI and HindIII linker sites at each end, were inserted into the multiple cloning site of the pAC adenoviral plasmid downstream of the CMV promoter/enhancer. The inserted fragment of the pol III promoter and the anti-erbB2 ribozyme for Ad-p53/erbB2Rz were constructed from two synthesized oligonucleotides; 5 0 -TTAC TAGTAGCAGAGTGGCGCAGCGGAAGCGTGCTG GGCCCATAACCCAGAGGTCGATGGATCGAAAC Figure 2 Construction of anti-erbB2 ribozyme. Anti-erbB2 ribozyme is driven by a CMV promoter in Ad-erbB2Rz and by a pol III promoter in Ad-p53/erbB2Rz. The ribozyme was designed to hybridize to erbB2 RNA at the sequence of oligoribonucleotide #824 (codon 70) to #837 (codon 74), and to cleave the RNA at the GUC site downstream of oligoribonucleotide #831.
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0 and 5 0 -TTACTAGTGCGCAAA AAAATCGATagcctgtttcgtcctcacggactcatcagcttcctGGC GCGCCAGAGGATGGTTTC-3 0 (small letters indicate sequences of anti-erbB2 ribozyme including AscI and ClaI restriction sites at each end, thus enabling easy replacement of any constructed oligonucleotides cassette). These oligonucleotides harbor an overlapping 17-mer, and were hybridized and extended. Resultant oligonucleotides have a SpeI restriction site at both ends. The constructed DNAs of pol III-erbB2 ribozyme were inserted into the SpeI digestion site located upstream of the CMV promoter/enhancer of pAC (i.e., outside of the original frame of the adenoviral genome). 13 The sequence of each constructed plasmid was confirmed by direct sequencing. The resultant pAC harboring the respective therapeutic gene was cotransfected into the human embryonal kidney cell line 293 along with the adenoviral shuttle plasmid pJM17. The constructed adenoviruses were plaque purified three times, and the correct insertion of transgenes in each adenovirus was reconfirmed by direct sequencing. The viruses were amplified in 293 cells, purified by commercially available viral purification kit (Virapur LLC, San Diego, CA), and titrated with the use of the plaque-forming assay. An adenovirus that expresses reporter gene b-galactosidase (Ad-LacZ) was used as a control adenovirus in infectivity and cell viability assays. Every batch of purified adenovirus was analyzed by a polymerase chain reaction (PCR) specific for detection of the adenoviral E1 region to screen for potential contamination by wild-type adenovirus. No contamination was recognized in any of the viral batches used in this study. 14 
Cell line
The human bladder cancer cell line EJ was used. A point mutation at exon 5 of the p53 gene in this cell line was confirmed by direct sequencing, which revealed a TAC to TAG (stop codon) mutation of the codon 126. No expression of p53 protein was detectable by Western blot analysis or immunocytochemical staining. Expression of the erbB2 protein was demonstrated by Western blot analysis of this cell line.
Adenoviral infectivity into EJ cells
The infection efficacy of the adenovirus was analyzed with the use of Ad-LacZ. A total of 2000 EJ cells were seeded in each well of a 96-well cell culture plate and incubated at 371C. The cell number was determined 24 h after seeding, serial multiplicity of infection (MOI) of AdLacZ in 100 ml of Dulbecco modified Eagle's medium (DMEM) with 2% fetal bovine serum (FBS) was added, and the cells were incubated for another 2 h. The adenoviral solution was exchanged to DMEM with 10% FBS, and LacZ staining was performed 24 h after adenoviral infection. The ratio of adenovirus-infected blue-stained cells in 400 cells was counted with the use of a light microscope. EJ cells were infected with adenovirus in approximately 30% at 1 MOI, 90% at 10 MOI, and 100% at 100 MOI.
Transduction of p53 in EJ cells
The expression of p53 RNA was semiquantified by reverse transcriptase-PCR (RT-PCR) in parent cells and cells infected with each adenovirus. EJ cells grown to 80% confluency were infected with Ad-p53, Ad-erbB2, Adp53/erbB2Rz, Ad-LacZ, and control medium, respectively. Viral titer at 1 MOI was used in the analysis for collecting sufficient quantities of RNA. The total RNA of parent cells and cells with adenoviral infection was extracted 48 h after adenoviral infection with the use of commercial Trizol agent (GIBCO-BRL, Grand Island, NY). Reverse transcription was performed with the use of AMV-RT, and PCR was conducted with p53-specific primers 5
0 -TGATGCTGTCCCCGGACGATA-3 0 and 5 0 -GATGCTGAGGAGGGGCCAGAC-3 0 as described elsewhere. 15 The PCR products were separated by electrophoresis, visualized by SYBR green (Molecular Probes Inc., Eugene, OR), and standardized with b-actin by an image analyzer LAS-1000plus (Fujifilm, Tokyo, Japan).
Expression of the p53 protein was evaluated by immunocytochemical staining. One million EJ cells were seeded in a poly-L-lysin precoated LabTech chamber (Nalge Nunc, Rochester, NY), and the adenoviruses were infected 24 h later at 1 MOI. At 24 h after the adenoviral infection, the wells were washed with phosphate-buffered saline (PBS) twice, soaked with 200 ml of 70% methanol for 15 min, and rinsed with 100 ml of PBS. Subsequently, the cells were incubated with H 2 O 2 for 10 min and incubated with goat serum albumin for an hour to block background staining. Primary monoclonal antibody p53 DO-7 (Novocastra, Newcastle, UK) at a concentration of 1:100 was introduced into each well, and the chambers were placed at 41C overnight. The primary antibody was then discarded, and the cells were rinsed with PBS twice. The chambers were then incubated with biotinylated secondary antibody (goat antimouse IgG at a concentration of 1:200) for 20 min, followed by two washing steps with PBS. After a 20-min incubation with HRP-Streptavidin, immunoreactivity was assessed with the use of AEC solution (Dako, Santa Barbara, CA).
Inhibition of erbB2 expression
The RNA expression of erbB2 was semiquantified by RT-PCR in the parent cells and the cells infected with each adenovirus at 1 MOI. The primers used for amplification of erbB2 were 5 0 -GAAGGTGAAGGTGCTTGGATC TGG-3 0 and 5 0 -TAGCTCATCCCCTTGGCAATCTGC-3 0 . The PCR products were separated electrophoretically, visualized by SYBR green, and standardized with actin under an image analyzer LAS-1000plus. The expression of erbB2 protein was quantified by Western blot analysis. The protein of EJ cells (parent cells and cells infected with each of the three different adenoviruses at 1 MOI) was extracted 48 h after adenoviral infection with the use of a cell lysate buffer (50 mmol/l TRIS pH 8, 5 mmol/l EDTA, 150 mmol/l NaCl, 0.5% NP-40, with protease inhibitor) and sonication. The protein concentration was measured with the use of a commercial protein assay kit (Pierce, Rockford, IL). Rabbit anti-c-erbB2 polyclonal antibody (Dako) was used as the primary antibody, and a goat antiactin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a dilution of 1:1000 for standardization. In all, 15 mg of protein extract were separated on a SDS-PAGE gel and transferred to a PVDF membrane (Amersham Biosciences, Piscataway, NJ). Blots were blocked with Block Ace (Dainippon Pharmacy, Osaka, Japan). The primary antibodies were diluted with 10% Block Ace and 0.1% Tween 20 in PBS. Horseradish peroxidase-conjugated secondary antibody was diluted 1:3000 in Block Ace/Tween 20/PBS. Antigens on the membrane were detected with ECL Plus regents (Amersham Biosciences), imaged by LAS-1000plus, and quantified by Image Gauge (Fujifilm).
Cell viabilty assay after respective single adenoviral infection In all, 2000 EJ cells were seeded into each well of 96-well cell culture plates and incubated at 371C. The cell number was counted 24 h after seeding, and four kinds of adenoviral vector in 100 ml of DMEM with 2% FBS were infected at serial MOIs. In brief, quadruplicated wells were treated for 2 h with Ad-p53, Ad-erbB2Rz, Ad-p53/erbB2Rz, Ad-LacZ, and control DMEM solution, respectively. MOIs 0.1, 1, and 10 were used. The adenoviral solution was exchanged for complete DMEM medium, and the cell viability was measured at various time points by ELISA with the use of MTT agent (Sigma, St Louis, MO).
Additive cytotoxic effect by the combination of Ad-p53 and Ad-erbB2Rz and by monotherapy with Ad-p53/erbB2Rz In all, 2000 EJ cells were seeded into each well of 96-well cell culture plates and incubated at 371C. The cell number was counted 24 h after seeding, and the adenoviral vectors were infected with Ad-p53 and Ad-erbB2Rz or with Adp53/erbB2Rz only at serial MOIs. In the combination therapy, cell viability was examined in two different viral titers. In one series, each well contained the same total amount of adenovirus as that in the monotherapy, whereas each well in the other series contained two-fold higher titers than the monotherapy. Briefly, quadruplicated wells were treated with (1) control medium, (2) the combination adenoviral solution of Ad-p53 and AderbB2Rz at a total amount of 1 or 10 MOIs (i.e., 0.5 or 1 each), (3) the combination adenoviral solution of Ad-p53 and Ad-erbB2Rz at a total amount of 2 or 20 MOIs (i.e., 1 or 10 each), and (4) Ad-p53/erbB2Rz at 1 or 10 MOIs. Therefore, the total MOIs of solutions 2 and 4 were the same, and those of solution 3 contain two-fold higher MOIs of adenoviruses than solutions 2 and 4. The cells were incubated for 2 h, and viral solution was exchanged for normal medium. The cell viability was then assayed over time with use of MTT agent.
Statisitical analysis
In the cytotoxicity assay, the differences in cell growth after each treatment were analyzed by analysis of variance; the differences were considered significant when the P-value was o0.05.
Results
Transduction of p53 into EJ cells
As assayed by semiquantitative RT-PCR, cells infected with Ad-p53 and Ad-p53/erbB2Rz exhibited increased p53 RNA expression (Figure 3a) . RNA expression, standardized by b-actin was 1.88-and 2.25-fold higher in Ad-p53-and Ad-p53/erbB2Rz-infected cells, respectively, compared with the parent cells. (Figure 4b and d) shows the results of immunocytochemical staining with a monoclonal antibody specific for p53. The expression of p53 was recognized in cells infected with only Ad-p53 or Ad-p53/erbB2Rz. Expression of p53 was not recognized in the parent EJ cells and the cells treated with AderbB2Rz.
Inhibition of erbB2 expression RNA expression of erbB2 was downregulated by treatment with Ad-erbB2Rz and Ad-p53/erbB2Rz. RNA expression was reduced by 29 and 19%, respectively, in cells infected with Ad-erbB2Rz and Ad-p53/erbB2Rz, compared with the parent cells (Figure 3b) . The expression of erbB2 protein was also suppressed by the infection of Ad-erbB2Rz (53% inhibition) and Ad-p53/erbB2Rz (65% inhibition) as shown by quantitative analysis of the Western blot analyses ( Figure 5 ). These findings demonstrated that both CMV and pol III promoters achieved sufficient erbB2 suppression efficacy. 
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Morphologic alterations in adenovirus-infected cells
With regard to cell morphology, nuclei were condensed and the cytoplasm had a shrunken appearance after administration of the therapeutic adenoviral vectors (Figure 4 ). These findings were most remarkable in cells infected with Ad-p53/erbB2Rz (Figure 4d ). Moderate similar morphological alterations were seen in Ad-p53-infected cells (Figure 4b) , and slight shrinkage of cytoplasm was recognized in cells infected with AderbB2Rz (Figure 4c ).
EJ cell viability after respective adenoviral infection EJ cell growth was inhibited by infection with each adenoviral vector encoding a therapeutic gene at 1 MOI (Figure 6 ). Remarkable cytotoxicity was seen after infection with Ad-erbB2Rz (P ¼ 0.0046) and Ad-p53/ erbB2Rz (P ¼ 0.0033). Ad-p53 demonstrated moderate cytotoxicity (P ¼ 0.0198). Ad-LacZ also showed slight cell growth inhibition, but it did not differ remarkably from parent cell growth (P ¼ 0.1745). At 10 MOI, cell growth inhibition was more pronounced in cells infected with Ad-p53/erbB2Rz, Ad-erbB2Rz, and Ad-p53; almost no cell growth was recognized in cells treated with Ad-p53/ erbB2Rz. Obvious cell growth inhibition was recognized by infection with Ad-LacZ at 10 MOI, pointing to nonspecific cytotoxicity.
EJ cell viability after treatment with combination of adenoviruses
Ad-p53/erbB2Rz demonstrated remarkable cytotoxicity at 1 MOI as seen in the previous analysis, and the combination of 1 MOI of each virus (i.e., 1 MOI Ad-p53 and 1 MOI Ad-erbB2Rz) also demonstrated obvious cytotoxic effects (Po0.0001; Figure 7 ). Although cell growth inhibition was shown after treatment with a combination of adenoviruses at a total MOI of 1 (i.e., 0.5 MOI Ad-p53 and 0.5 MOI Ad-erbB2Rz; Po0.0001), the efficacy was less significant than that of Ad-p53/ erbB2Rz (Po0.0001) when the total amount of viruses was the same. This result demonstrated the superior therapeutic efficacy of monotherapy with Ad-p53/ erbB2 over the combination of Ad-p53 and Ad-erb B2Rz when the total amount of viral titers was identical. At 10 MOI, inhibition of cell growth by each adenovirus was remarkable, and almost no cell growth was observed. Antitumor efficacy of dual-gene-expressing adenovirus A Irie et al
Discussion
In the field of cancer gene therapy, transduction of tumorsuppressor genes and inhibition of oncogenic activity are strategies that have been extensively examined. However, the therapeutic efficacy of each of these strategies alone may not be sufficient to control cancer growth, and combination approaches with irradiation or chemotherapeutic agents have been investigated. These insufficiencies might be caused by the multiple genetic alterations present in cancer progression. The combination of tumorsuppressor therapy and antioncogene therapy has not been examined to date. In the present study, both of these strategies were combined to enhance the therapeutic efficacy. Furthermore, two therapeutic genes were driven simultaneously from a single adenoviral vector to reduce the total amount of viral titers to minimize the vectorrelated nonspecific toxicity. The potential additive therapeutic effect with less vector-related cytotoxicity by a dual-gene-expressing adenovirus was recognized. We constructed an adenovirus, which expresses two therapeutic genes simultaneously, by inserting 2 units for expressing therapeutic genes (i.e., promoter, therapeutic gene, and termination signal) in tandem sequence into a type 5, E1-deleted adenovirus. This dual-gene-expressing adenoviral vector construct employed a CMV promoter for p53 expression and a pol III promoter for driving the anti-erbB2 ribozyme. The CMV promoter is a well-known strong constitutive promoter for continuous expression of transgenes. The pol III promoter with its simple and small structure is advantageous for driving small molecules such as antisense oligonucleotides and ribozymes. 12 Smaller sequences might have a benefit in the insertion of recombination units because of the limited space of the adenoviral genomic structure. The pol III promoter could be inserted upstream of the transcription initiation site of the CMV promoter/enhancer where the insertion did not affect the function of the CMV promoter or the adenoviral construct. Furthermore, when synthesizing the pol III-ribozyme sequence, we included specific digestion sites at both ends of the ribozyme sequences, which facilitated insertion of any therapeutic gene sequence to be driven by the pol III promoter. Although we did not evaluate the difference in ribozyme expression efficacy of the two different promoters, similar suppression of erbB2 RNA was recognized by RT-PCR in both Ad-erbB2Rz (CMV) and Ad-p53/erbB2Rz (pol III). Furthermore, downregulation of the erbB2 protein was slightly more pronounced by Ad-p53/erbB2Rz (pol III) than that achieved by Ad-erbB2Rz (CMV), as shown by Western blot analysis. These data demonstrated that the pol III promoter could drive a ribozyme sufficiently, at least to a level similar to that of the CMV promoter.
Adenoviral vectors are one of the most widely used delivery systems in clinical cancer gene therapy trials. However, it has been reported that the infectivity of adenoviruses depends on the targeted cell and that viral infectivity is at least partially associated with the expression of the adenoviral receptor (i.e., coxsackieadenovirus receptor (CAR). It has been reported that bladder cancer loses CAR expression, especially in invasive diseases. 16 This finding might be a major obstacle for therapeutic strategies employing adenoviral vectors. As we have shown in a previous study, expression of CAR is low in EJ cells, and adenoviral infectivity is not prominent, compared with the low-grade bladder cancer cell line RT-4. We reported extremely low infectivity using different batches of Ad-p53: an MOI of 10 7 was necessary to infect 100% of cultured EJ cells. 15 Modification of viral purification methods was shown to enhance the adenoviral infectivity of EJ cells. Differences in titration also led to a different result of adenoviral infectivity in each study. We also previously reported better adenoviral infectivity in vivo compared with in vitro, and in higher cell density compared with lower cell density in vitro. 15 These results might be important for evaluating the data reported in the literature. Recently, several strategies have been examined for improving the adenoviral infectivity of bladder cancer cells: The application of CAR cDNA, syn-3, gelfoam, and connectin 26 has demonstrated favorable results. [17] [18] [19] [20] These results show that an adenovirus can be adopted as a delivery vehicle for gene therapy of bladder cancer. In fact, adenoviral vectors have been utilized in clinical trials of p53 transduction strategies by intravesical instillation, and sufficient gene transduction efficiency has been reported. 21, 22 Further improvement of the host environment for susceptibility to delivery vehicles and enhancement of transduction efficacy of delivery systems might lead to improved therapeutic efficiency.
Antitumor efficacy against various cancers by the restoration of wild-type p53 has been widely examined in preclinical and clinical settings, and encouraging results have been demonstrated. Restoration or overexpression of p53 is known to achieve various antitumor activities, which include induction of apoptosis, inhibition of cell proliferation, antiangiogenesis, and repair of damaged genes. These antitumor mechanisms of p53 are known to be dependent in part on the p53 dose: A low concentration of p53 causes cell-cycle arrest, which switches to apoptosis as p53 concentrations increase. The mechanisms of p53 function are also reported to differ in respective cancer cell lines. 23, 24 In our previous study using EJ cells, remarkable apoptosis was not recognized, and the genes related to induction of apoptosis were not increased by relatively low doses (i.e., 1 MOI) of p53. It might be important to clarify, in future investigations, the detailed mechanisms of antitumor effects by p53 in respective cancer cells and to find the adequate dosage of p53 for improving the therapeutic efficacy. Induction of p53 is also known to improve chemosensitivity and radiosensitivity of cancer cells. [25] [26] [27] These observations also might have benefit in enhancing the therapeutic efficacy of advanced bladder cancers.
In the present study, the proto-oncogene erbB2 was chosen as a target gene for bladder cancer treatment because of its high incidence of altered expression in this disease and its close relation to the atypical grade of the tumors. As a strategy for inhibiting oncogenic activity of erbB2, we employed a hammerhead ribozyme for interfering with RNA transcription. The structure of the hammerhead ribozyme is simple and small, and it is easy to design against any target RNA. Therapeutic efficacy of antioncogene ribozymes has been extensively demonstrated both in vitro and in vivo, and the application of this strategy against bladder cancer also has been shown. 28, 29 We obtained remarkable cell growth inhibition and significant downregulation of both RNA and their encoded protein expression levels of erbB2 by the transduction of anti-erbB2 ribozyme. However, some complicated matters have been reported regarding the expression of erbB2 RNA and protein. Coombs et al. 30 and Sauter et al. 31 reported that altered expression of erbB2 RNA and protein did not always correlate. That overexpression of erbB2 protein is not always associated with erbB2 gene amplification also has been reported. 32, 33 This finding might be a possible obstacle for the RNA interference strategies when setting the erbB2 gene as the target. In contrast, it has been reported that the antitumor efficacy of anti-erbB2 ribozyme did not depend on the status of erbB2 expression in breast cancer cells. 34 These discrepancies are not well clarified: Either the expression between RNA and protein is truly different, or the finding may simply be due to the specificity of antibodies against erbB2 used in each study or to the heterogenic distribution within the tumors. In future investigations, the detailed mechanisms of the transcription from RNA to protein, biological functions, and cellular localization of erbB2 need to be elucidated.
We demonstrated superior anticancer efficacy with reduced vector-related toxicity by a dual-gene-expressing adenoviral vector against bladder cancer cells. This strategy could be adapted to the treatment of not only bladder cancer but also for any kind of cancer by selecting the respective appropriate target genes. Since the size of therapeutic genes that could be recombined in the delivery vehicles is limited, the optimization of promoter and therapeutic gene sequences might be required. With these restrictions, the utilization of a pol III promoter and small therapeutic molecules like ribozymes, antisenses and siRNAs might be favorable tools. In the adenoviral vector constructed in this study, we can recombine easily any sequences of therapeutic genes to be driven by CMV and pol III promoters at the respective cloning site. Future studies by different combinations of therapeutic genes against various cancers might be encouraged.
